Baseline characteristics Total (n = 1136)
Men/Women, n (%) 770 (67.8)/366 (32.2)
Age at HAART initiation (years)  
Mean (standard deviation) 40 (10.4)
[18–50[, n (%) 963 (84.8)
[50–82], n (%) 173 (15.2)
Mode of HIV acquisition, n (%)  
Heterosexual 552 (48.6)
Homosexual/Bisexual 389 (34.2)
Injection drug use 84  (7.4)
Other/Unknown 111 (9.8)
Year of first HAART, n (%)  
[2000–2001] 313 (27.6)
[2002–2003] 242 (21.3)
[2004–2005] 253 (22.3)
[2006–2008] 328 (28.8)
Therapeutic education, Yes, n (%) 226 (19.9)
First HAART regimen, n (%)  
2NRTI+1PI/1PIb 406 (35.7)
2NRTI+1NNRTI 380 (33.5)
Other regimens 350 (30.8)
Death, Yes, n (%) 0   (0.0)
AIDS-defining illness at HAART initiation, n (%)  
Yes 151 (13.3)
Missing data 44  (3.9)
Duration HIV seropositivity (years)  
Mean (standard deviation) 4.7 (5.7)
CD4 cell count at HAART initiation (cells/mm3)  
Mean (standard deviation) 264.9 (196.6)
Missing data, n (%) 210 (18.5)
Viral load at HAART initiation (log10 copies/mm3)  
Mean (standard deviation) 4.6 (1.1)
Missing data, n (%) 307(27.0)
PIb = boosted protease inhibitor  
Table 1: Characteristics at treatment initiation of the 1136 participants receiving first-line HAART between January 1, 2000 and June 30, 2008 among patients treated at Toulouse Teaching Hospital.